Lipigon Pharmaceuticals AB

Equities

LPGO

SE0015382072

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:15:24 2024-04-26 am EDT 5-day change 1st Jan Change
0.3595 SEK +9.94% Intraday chart for Lipigon Pharmaceuticals AB +6.05% -16.59%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Lipigon Pharmaceuticals’ Lipisense Gets Swedish Regulators' Nod for Mid-stage Study MT
The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense CI
Lipigon Pharmaceuticals AB Announces Lipisense Progressing to Phase II Trials CI
Lipigon Pharmaceuticals AB Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ® CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Lipigon Applies for Clinical Trial Phase II for Lipisense CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Lipigon Pharmaceuticals AB Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial CI
Lipigon Pharmaceuticals Surges 40% on Lipisense Development, Licensing Deal in China MT
Lipigon Announces Development and License Agreement with Leaderna Therapeutics Ltd CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Lipigon Announces Further Positive Data from Phase I Trial of Lipisense CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Lipigon Pharmaceuticals AB Announces Positive Top-Line Data from Phase I Clinical Study of Lipisense CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Lipigon Pharmaceuticals AB Announces Liver-Specific Treatment of Target Protein ANGPTL4 Is Effective and Safe CI
Lipigon Pharmaceuticals AB Announces First-In-Human Phase I Trial with Lipigon's Lipid-Lowering Candidate Lipisense CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Lipigon Receives CTA Approval for Lipid-Lowering Candidate Lipisense CI
Lipigon Pharmaceuticals AB and HitGen Inc. Announce Achievement of an Important Milestone in Dyslipidemia Project CI
Lipigon Pharmaceuticals AB Submits CTA for Lipid-Lowering Drug Candidate Lipisense CI
Lipigon Pharmaceuticals AB Confirms Patent Application for Drug Candidate Lipisense in US CI
Chart Lipigon Pharmaceuticals AB
More charts
Lipigon Pharmaceuticals AB is a Sweden-based project portfolio company. Lipigon's business concept is to develop medicines with new, unique mechanisms of action (so-called first-in-class) for diseases that lack adequate treatment. The Company develops medicines with a focus on diseases where the body's ability to handle fats is disturbed, so-called lipid-related diseases, and where there are unmet medical needs. Initially, the Company's development focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in the clinical development. It creates the conditions for studies with fewer patients and a shorter path to market approval and thus a reduced development risk.
More about the company

Chiffre d''affaires - Rate of surprise

  1. Stock Market
  2. Equities
  3. LPGO Stock
  4. News Lipigon Pharmaceuticals AB
  5. Lipigon Pharmaceuticals Surges 40% on Lipisense Development, Licensing Deal in China